Narcolepsy Therapeutics Market, Size, Share, Outlook and Growth Opportunities 2019-2026
Global Narcolepsy Therapeutics Market is segmented By Disease Type (Daytime Extreme Sleepiness, Cataplexy, Others), By Therapeutic Type (Sodium Oxybate, Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor,
(EMAILWIRE.COM, March 26, 2020 ) Market Overview
The Global Narcolepsy Therapeutics Market is expected to grow at a high CAGR during the forecasting period (2019-2026)
Narcolepsy is a rare sleep disorder associated with uncontrollable sleepiness and frequent daytime sleeping. The condition is characterized by several symptoms, including excessive daytime sleepiness (EDS), cataplexy, automatic behaviors, hallucinations, and sleep paralysis. Narcolepsy has no cure, but drug therapies and lifestyle changes can often help improve symptoms.
Download free sample: https://www.datamintelligence.com/download-sample/narcolepsy-therapeutics-market
Market Dynamics
• The global narcolepsy therapeutics market is growing due to several factors such as the rising prevalence of narcolepsy, growing narcolepsy awareness programs, increasing research & development for new drugs and treatment for narcolepsy.
• The narcolepsy affects 0.03 to 0.16% of the general population with incidence 1/2,000 globally. The American Academy of Sleep Medicine's International Classification of Sleep Disorders has classified two forms of narcolepsy: narcolepsy with cataplexy (also called narcolepsy type 1 (NT1)) and narcolepsy without cataplexy (also known as narcolepsy type 2 (NT2)). The NT1 is most commonly caused by a deficiency of central nervous system (CNS) hypocretin (hcrt also called orexin) in the hypothalamus. The prevalence of narcolepsy type 1 is 25 to 50 per 100,000 people and 20 to 34 per 100,000 people for narcolepsy type 2.
• This growth of the market is also driven by the robust pipeline portfolio. There are currently few approved therapies available for narcolepsy. Some of the approved drugs for narcolepsy are Xyrem (sodium oxybate), amphetamine, Nuvigil (armodafinil), Provigil (modafinil), and methylphenidate. The majority of the drugs are also used off-label for narcolepsy, including stimulants, depressants, and antidepressants. In October 2018, the Food and Drug Administration has cleared Xyrem (sodium oxybate) oral solution to treat cataplexy and excessive daytime sleepiness in patients ages 7-17 with narcolepsy. The two highest selling drugs are expected to be Avadel’s/ Sodium oxybate ER and Jazz Pharmaceutical’s/JZP-258, which both address some of the unmet needs in the market.
• However, market growth is hindered by the adverse effects and risks associated with narcolepsy drugs and delayed diagnosis.
Market Segmentation
• On the basis of disease type, the narcolepsy therapeutics market is segmented into daytime extreme sleepiness (DES), cataplexy, and others. Among these, the daytime extreme sleepiness (DES) accounted for the largest market share in 2018, due to the rising prevalence of narcolepsy and other sleep disorders. Daytime extreme sleepiness is one of the most common sleep-related patient symptoms affecting an estimated 20% of the population. Obstructive sleep apnea is a particularly significant cause of excessive daytime sleepiness. An estimated 26 to 32% of adults are at risk of or have obstructive sleep apnea, and the prevalence is expected to increase during the forecast period. About 20% of adults in the United States report a level of daytime sleepiness sufficient to interfere with daily activities, and excessive daytime sleepiness is the leading symptom of patients presenting to sleep clinics. On the other hand, the cataplexy segment is expected to grow at the fastest CAGR during the forecast period (2019-2026), as patients suffering from cataplexy tend to lose muscle control and the majority of the narcolepsy patients have this symptom. The cataplexy is a common type of narcolepsy disorder, which affects nearly around 0.02% to 0.05% of the population globally.
• By therapeutics type, the narcolepsy Therapeutics market is segmented into central nervous system stimulants, sodium oxybate, tricyclic antidepressants, selective serotonin reuptake inhibitors, and others. Among these, the sodium oxybate segment held the largest market share in 2018, as these drugs are highly effective to treat daytime extreme sleepiness and cataplexy. Sodium oxybate (Xyrem) is the sodium salt of gamma-hydroxybutyrate (GHB), a naturally occurring substance in the brain. Sodium oxybate is quite different from the other medications used to treat narcolepsy as it is a sedating liquid taken at bedtime instead of a usual pill taken during the day. Its effects last only a few hours, a second dose is taken three to four hours later. These two doses produce deep sleep through much of the night, and after several weeks of regular use, sodium oxybate usually improves daytime sleepiness and cataplexy. On the other hand, the selective serotonin reuptake inhibitor segment is expected grow at the fastest CAGR during the forecast period (2019-2026), due to rising R&D activities for the development of these type of drugs by the major players in the market.
Geographical Analysis
• North America holds the dominant market share for narcolepsy therapeutics in 2018, and it is expected to maintain the growth over the forecast period, due to the factors, such as rising prevalence of narcolepsy and other sleep disorders, robust pipeline product for the treatment of narcolepsy by manufactures, and rising awareness towards this sleep disorder. In the United States, around 1 among the 2000 patients are affected by narcolepsy disorder. The prevalence in North America is around 0.07%. Thus, the growing measures in therapeutics for diagnosis and treatment of narcolepsy lead to the growth of the market in the North America region during the forecast period (2019-2026). For instance, on August 15th, 2019, the US FDA has approved pitolisant (Wakix, Harmony Biosciences) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. Pitolisant is the first and only treatment approved for patients with narcolepsy that is not scheduled as a controlled substance by the US Drug Enforcement Administration. Pitolisant is expected to be commercially available to healthcare professionals and appropriate patients in the US in the fourth quarter of 2019.
Competitive Landscape
• The narcolepsy therapeutics market is highly competitive with presence of a large number of players including Jazz Pharmaceutical plc, Arena Pharmaceutical, Inc., Ligand Pharmaceuticals Inc., Bioprojet Pharma, Novartis, Teva Pharmaceutical Industries Ltd., Shinogi Inc., Takeda Pharmaceutical Company, Addrenex Pharmaceuticals, , among others hire Plc.
• The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the narcolepsy therapeutics market globally. For instance,
• In March 2019, Jazz Pharmaceuticals plc received the U.S. FDA approval for Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).
• In January 2018, Glenmark Pharmaceutical entered into a license agreement with Ligand Pharmaceuticals to use the full range of OmniAb platform to discover mono multispecific antibodies.
View full report: https://www.datamintelligence.com/research-report/narcolepsy-therapeutics-market
Enquiry before buying: https://www.datamintelligence.com/enquiry/narcolepsy-therapeutics-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
The Global Narcolepsy Therapeutics Market is expected to grow at a high CAGR during the forecasting period (2019-2026)
Narcolepsy is a rare sleep disorder associated with uncontrollable sleepiness and frequent daytime sleeping. The condition is characterized by several symptoms, including excessive daytime sleepiness (EDS), cataplexy, automatic behaviors, hallucinations, and sleep paralysis. Narcolepsy has no cure, but drug therapies and lifestyle changes can often help improve symptoms.
Download free sample: https://www.datamintelligence.com/download-sample/narcolepsy-therapeutics-market
Market Dynamics
• The global narcolepsy therapeutics market is growing due to several factors such as the rising prevalence of narcolepsy, growing narcolepsy awareness programs, increasing research & development for new drugs and treatment for narcolepsy.
• The narcolepsy affects 0.03 to 0.16% of the general population with incidence 1/2,000 globally. The American Academy of Sleep Medicine's International Classification of Sleep Disorders has classified two forms of narcolepsy: narcolepsy with cataplexy (also called narcolepsy type 1 (NT1)) and narcolepsy without cataplexy (also known as narcolepsy type 2 (NT2)). The NT1 is most commonly caused by a deficiency of central nervous system (CNS) hypocretin (hcrt also called orexin) in the hypothalamus. The prevalence of narcolepsy type 1 is 25 to 50 per 100,000 people and 20 to 34 per 100,000 people for narcolepsy type 2.
• This growth of the market is also driven by the robust pipeline portfolio. There are currently few approved therapies available for narcolepsy. Some of the approved drugs for narcolepsy are Xyrem (sodium oxybate), amphetamine, Nuvigil (armodafinil), Provigil (modafinil), and methylphenidate. The majority of the drugs are also used off-label for narcolepsy, including stimulants, depressants, and antidepressants. In October 2018, the Food and Drug Administration has cleared Xyrem (sodium oxybate) oral solution to treat cataplexy and excessive daytime sleepiness in patients ages 7-17 with narcolepsy. The two highest selling drugs are expected to be Avadel’s/ Sodium oxybate ER and Jazz Pharmaceutical’s/JZP-258, which both address some of the unmet needs in the market.
• However, market growth is hindered by the adverse effects and risks associated with narcolepsy drugs and delayed diagnosis.
Market Segmentation
• On the basis of disease type, the narcolepsy therapeutics market is segmented into daytime extreme sleepiness (DES), cataplexy, and others. Among these, the daytime extreme sleepiness (DES) accounted for the largest market share in 2018, due to the rising prevalence of narcolepsy and other sleep disorders. Daytime extreme sleepiness is one of the most common sleep-related patient symptoms affecting an estimated 20% of the population. Obstructive sleep apnea is a particularly significant cause of excessive daytime sleepiness. An estimated 26 to 32% of adults are at risk of or have obstructive sleep apnea, and the prevalence is expected to increase during the forecast period. About 20% of adults in the United States report a level of daytime sleepiness sufficient to interfere with daily activities, and excessive daytime sleepiness is the leading symptom of patients presenting to sleep clinics. On the other hand, the cataplexy segment is expected to grow at the fastest CAGR during the forecast period (2019-2026), as patients suffering from cataplexy tend to lose muscle control and the majority of the narcolepsy patients have this symptom. The cataplexy is a common type of narcolepsy disorder, which affects nearly around 0.02% to 0.05% of the population globally.
• By therapeutics type, the narcolepsy Therapeutics market is segmented into central nervous system stimulants, sodium oxybate, tricyclic antidepressants, selective serotonin reuptake inhibitors, and others. Among these, the sodium oxybate segment held the largest market share in 2018, as these drugs are highly effective to treat daytime extreme sleepiness and cataplexy. Sodium oxybate (Xyrem) is the sodium salt of gamma-hydroxybutyrate (GHB), a naturally occurring substance in the brain. Sodium oxybate is quite different from the other medications used to treat narcolepsy as it is a sedating liquid taken at bedtime instead of a usual pill taken during the day. Its effects last only a few hours, a second dose is taken three to four hours later. These two doses produce deep sleep through much of the night, and after several weeks of regular use, sodium oxybate usually improves daytime sleepiness and cataplexy. On the other hand, the selective serotonin reuptake inhibitor segment is expected grow at the fastest CAGR during the forecast period (2019-2026), due to rising R&D activities for the development of these type of drugs by the major players in the market.
Geographical Analysis
• North America holds the dominant market share for narcolepsy therapeutics in 2018, and it is expected to maintain the growth over the forecast period, due to the factors, such as rising prevalence of narcolepsy and other sleep disorders, robust pipeline product for the treatment of narcolepsy by manufactures, and rising awareness towards this sleep disorder. In the United States, around 1 among the 2000 patients are affected by narcolepsy disorder. The prevalence in North America is around 0.07%. Thus, the growing measures in therapeutics for diagnosis and treatment of narcolepsy lead to the growth of the market in the North America region during the forecast period (2019-2026). For instance, on August 15th, 2019, the US FDA has approved pitolisant (Wakix, Harmony Biosciences) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. Pitolisant is the first and only treatment approved for patients with narcolepsy that is not scheduled as a controlled substance by the US Drug Enforcement Administration. Pitolisant is expected to be commercially available to healthcare professionals and appropriate patients in the US in the fourth quarter of 2019.
Competitive Landscape
• The narcolepsy therapeutics market is highly competitive with presence of a large number of players including Jazz Pharmaceutical plc, Arena Pharmaceutical, Inc., Ligand Pharmaceuticals Inc., Bioprojet Pharma, Novartis, Teva Pharmaceutical Industries Ltd., Shinogi Inc., Takeda Pharmaceutical Company, Addrenex Pharmaceuticals, , among others hire Plc.
• The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the narcolepsy therapeutics market globally. For instance,
• In March 2019, Jazz Pharmaceuticals plc received the U.S. FDA approval for Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).
• In January 2018, Glenmark Pharmaceutical entered into a license agreement with Ligand Pharmaceuticals to use the full range of OmniAb platform to discover mono multispecific antibodies.
View full report: https://www.datamintelligence.com/research-report/narcolepsy-therapeutics-market
Enquiry before buying: https://www.datamintelligence.com/enquiry/narcolepsy-therapeutics-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results